Curated News
By: NewsRamp Editorial Staff
September 04, 2024
Clene Inc. to Present at H.C. Wainwright 26th Annual Global Investment Conference
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- Clene (NASDAQ: CLNN) will present at the H.C. Wainwright 26th Annual Global Investment Conference, providing an opportunity for potential investors.
- Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases.
- Clene is dedicated to improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, potentially improving the lives of patients.
- CNM-Au8(R) is an investigational first-in-class therapy that targets mitochondrial function, presenting a potential breakthrough in the treatment of neurodegenerative diseases.
Impact - Why it Matters
This news matters as it highlights a clinical-stage biopharmaceutical company's efforts to develop innovative therapies for neurodegenerative diseases like ALS and MS. The presentation at the conference provides an opportunity for investors to learn about Clene Inc.'s promising developments in the field of mitochondrial health and neuronal function protection.
Summary
Clene Inc. and its subsidiary, Clene Nanomedicine Inc., will present at the H.C. Wainwright 26th Annual Global Investment Conference and host 1x1 investor meetings. The virtual presentation is scheduled for September 9, 2024, at 7 a.m. EST. The company is focused on improving mitochondrial health to treat neurodegenerative diseases, including ALS and MS. CNM-Au8(R) is an investigational first-in-class therapy that targets mitochondrial function and the NAD pathway while reducing oxidative stress.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene Inc. to Present at H.C. Wainwright 26th Annual Global Investment Conference
